In clinical cancer trials, Debio 1143 was shown to be highly efficacious in decreasing cIAP1 in patient-derived PBMCs at doses above 80 mg and it was well tolerated up to 900 mg [39, 40]. The gene discussed is BIRC2; the disease is cancer.